Deciphera Pharma is a science-driven company dedicated to discovering, developing, and delivering groundbreaking medicines that have the power to transform the lives of cancer patients. Through their innovative drug discovery platform and deep expertise in kinase biology, they design kinase inhibitors that target the switch pocket region of the kinase. This unique approach aims to create potentially transformative medicines with higher and more durable rates of response.

With a patient-inspired focus, Deciphera Pharma is committed to improving treatment outcomes for those affected by cancer. They have a diverse pipeline of differentiated, wholly-owned, orally administered drug candidates. Their flagship product, QINLOCK®, has garnered a strong reputation and success in the United States.

With a talented team of over 250 employees and a robust clinical development program, Deciphera Pharma is at the forefront of the fight against cancer